

Thursday 4th November

1830 - 1930	Welcome & Keynote Address	
<i>Session Chairs: Rick Kefford (Australia)</i>		Parkside Auditorium
1830 - 1930	Evolving Melanoma Therapeutics	
	<u>Keith Flaherty</u>	

Friday 5th November

0715 - 0730	GSK Program: Adjuvant Therapy – What lies ahead	
<i>Session Chairs: Richard Kefford & Peter Hersey</i>		Parkside 110A & 110B
0715 - 0730	What is the promise and risk of selective BRAF inhibitors in adjuvant therapy?	
	<u>Lead discussants: Jeff Sosman, Reinhard Dummer</u>	
0730 - 0745	How can we target immunotherapy more effectively? Biomarker studies	
	<u>Lead discussants: Jonathan Cebon, Graham Mann, John Kirkwood</u>	
0745 - 0800	What lies ahead in choice of antigens for immunotherapy?	
	<u>Lead discussants: Rod Dunbar, Jurgen Becker</u>	
0800 - 0815	Questions and Discussion	
0830 - 1030	Targeted Therapies I	
<i>Session Chairs: Dirk Schadendorf (Germany) & Rod Dunbar (New Zealand)</i>		Parkside Auditorium
0830 - 0900	Selective inhibition of oncogenic BRAF V600E/K/D by GSK2118436: Evidence of clinical activity in subjects with metastatic melanoma	
	<u>Richard Kefford</u>	
0900 - 0930	An open-label, multicenter phase 2 study of continuous oral dosing of RG7204 (PLX4032) in previously treated patients with BRAF V600E mutation-positive metastatic melanoma	
	<u>Jeff Sosman</u>	
0930 - 1000	Feedback inhibition of RAF/MEK signalling	
	<u>Neal Rosen</u>	
1000 - 1030	BRAF/CRAF switching	
	<u>Richard Marais</u>	
1030 - 1100	Morning tea	
1100 - 1300	Melanoma Stem Cells	

* Program current as of 27 October 2010 and is subject to change.

Sponsored Symposia Programs

GSK Program – Platinum Sponsor

Friday 5th November 2010

Catering – Breakfast

0700 - 0800	Adjuvant therapy - What lies ahead	
<i>Session Chairs: Richard Kefford & Peter Hersey</i>		Parkside 110A
0700 – 0715	Promise and Risks of selective BRAF inhibitors in Adjuvant therapy <i>Reinhard Dummer, Jeff Sosman</i>	
0715 – 0730	Is array data on melanoma LN biopsies good enough to stratify patients? <i>Jonathan Cebon, Graham Mann, Gajewski</i>	
0730 – 0745	How can we increase responses, reduce toxicity of anti CTLA 4/ PD1 antibodies. <i>Jeff Weber, Mario Sznol</i>	
0745 – 0800	Relative merits of CT antigens and synthetic long peptides in adjuvant immunotherapy. <i>Jonathan Cebon, Rod Dunbar</i>	

BMS Program – Gold Sponsor

Friday 5th November

Catering – Delegate Lunches

1300 - 1400	BMS Lunch Symposium	
<i>Session Chairs: Peter Hersey</i>		Parkside 110 A & B
1300 - 1305	Introduction <i>Peter Hersey</i>	
1305 - 1320	Cancer Vaccines. Successes and failures <i>Jonathan Cebon</i>	
1320 - 1340	Overcoming Immunologic Tolerance to Melanoma: Targeting CTLA-4 <i>F. Stephen Hodi</i>	
	Discussion	

Roche Program – Platinum Sponsor

Saturday 6th November 2010

Catering – Provide lunch boxes

1300 - 1400	Advanced Melanoma – Finding a Tailored Solution for Patients	
<i>Session Chairs: Richard Kefford</i>		Parkside 110A
1300 - 1305	Opening Remarks <i>Richard Kefford</i>	
1305 – 1315	The Evolution of Treatment for Advanced Melanoma: From Chemotherapy to Individualized Targeted Therapies <i>Grant McArthur</i>	
1315 – 1325	Pivotal Signal Transduction Pathways in Melanoma <i>Axel Hauschild</i>	
1325 – 1340	Advances in RAF Pathway Inhibitors for Advanced Melanoma <i>Jeffrey Sosman</i>	
1340 - 1400	Q&A and Closing Remarks <i>Richard Kefford</i>	

Abbott Program – Silver Sponsor

Saturday 6th November 2010

Catering – Wine and Canapés

1800 – 1900	Recent Advances in The Diagnosis of Melanoma	
<i>Session Chairs: Richard Scolyer</i>		Parkside 110A
1800 – 1830	Targeting Immunotherapy in Patients with Melanoma <i>Peter Hersey</i>	
1830 – 1900	FISH for Melanoma diagnosis – the MSKCC experience <i>Klaus Busam</i>	

0900 - 1800	International Melanoma Pathology Study Group	
<i>Session Chairs: Richard Scolyer, Raymond Barnhill</i>		Parkside 110A
0900 - 0910	Introduction	
	<u><i>Richard Scolyer; Raymond Barnhill</i></u>	
0910 - 0930	Spitzoid melanocytic neoplasms: Experience from the Graz study	
	<u><i>Lorenzo Cerroni</i></u>	
0930 - 0950	Molecular advances in melanoma	
	<u><i>Boris. Bastian</i></u>	
0950 - 1010	Lymphangiogenesis, lymphatic invasion, and melanoma	
	<u><i>David Elder</i></u>	
1010 - 1030	Diagnostic drift in melanoma: a 20 year study	
	<u><i>Lyn Duncan</i></u>	
1030 - 1100	Morning Tea	
1100 - 1120	The Royal College of Pathologists of Australasia's structured pathology reporting protocol for cutaneous melanoma	
	<u><i>Richard Scolyer</i></u>	
1120 - 1140	Unusual and rare variants of melanomas	
	<u><i>Stan McCarthy</i></u>	
1140 - 1200	The Atypical Spitz Tumor: The Michigan Experience	
	<u><i>Lori Lowe</i></u>	
1200 - 1220	Assessment of mitotic rate in thin melanoma.	
	<u><i>Jane Messina</i></u>	
1220 - 1230	Questions and Discussion	
1230 - 1400	Lunch	
<i>Session Chairs: Stan McCarthy, David Elder</i>		Parkside 110A
1400 - 1420	FISH - Applications and limitations for melanocytic lesions	
	<u><i>Klaus Busam</i></u>	
1420 - 1440	Evaluation of prognostic factors: The pathologist's perspective	

	<u>Chris Shea</u>
1440 - 1500	Atypical blue nevi and related melanomas
	<u>Raymond Barnhill</u>
1500 - 1520	Sentinel node biopsy: State of the art!
	<u>Alistair Cochran</u>
1520 - 1540	Pathological variation in diagnosis
	<u>Michael Piepkorn</u>
1540 - 1610	Afternoon Tea
1610 - 1630	New diagnostic entities
	<u>Martin C. Mihm</u>
1630 - 1650	Immunohistochemistry in melanoma
	<u>Gilles Landman</u>
1650 - 1710	An emerging role for microRNAs in Dermatopathology
	<u>Victor Tron</u>
1710 - 1730	Cytological diagnosis of melanoma
	<u>Rajmohan Murali</u>
1730 - 1800	Questions and Discussion

Thursday 4th November 2010

0830 - 1030		Primary Care & IMSCC Joint Plenary Session	
<i>Session Chairs: John Thompson, Axel Hauschild</i>		Parkside Auditorium	
0840 - 0910	Risk factors for melanoma		
	<u><i>Bruce Armstrong</i></u>		
0910 - 0940	Melanoma Biology Unmasked		
	<u><i>Hensin Tsao</i></u>		
0940 - 1015	Melanoma and personalised medicine		
	<u><i>Boris Bastian</i></u>		
1015 - 1030	Discussion		
1030 - 1100		Morning Tea	
1100 - 1300	1100 - 1300	Diagnosis and Staging	
	<i>Session Chairs: Alistair Cochran, Graham Stevens</i>		Parkside 110 A & B Combined
	1100 - 1120	Evidence for diagnostic techniques in primary melanoma	
		<u><i>Josep Malvehy</i></u>	
	1120 - 1220	Lentigo Maligna: evolving techniques for assessment and management	
			Parkside 110 A & B Combined
	1120 - 1132	Lentigo maligna: minimal criteria for pathological diagnosis	
		<u><i>Martin Mihm</i></u>	
	1132 - 1140	Confocal diagnosis of lentigo maligna	
		<u><i>Pascale Guitera</i></u>	
	1140 - 1148	Efficacy of imiquimod 5% cream for lentigo maligna as assessed following complete excision - a study of 43 patients	
		<u><i>Martin Haskett</i></u>	
1150 - 1200	Radiotherapy for lentigo maligna		
	<u><i>Angela Hong</i></u>		
1200 - 1210	Surgical management of lentigo maligna		
	<u><i>Ciaran Healy</i></u>		
1210 - 1220	What is the best treatment for lentigo maligna?		

		Moderated panel discussion	
	1220 - 1300	Sentinel Node Biopsy	
	<i>Session Chairs: Claus Garbe, Alessandro Testori</i>		Parkside 110 A & B Combined
	1220 - 1230	Technical Advances <i>Omgo Nieweg</i>	
	1230 - 1240	Is sentinel node biopsy 'standard of care' for melanoma in 2010? <i>Vernon Sondak</i>	
	1240 - 1250	Who should have sentinel node biopsy and who should not? <i>Daniel Coit</i>	
	1015 - 1030	Discussion	
1100 - 1300	1100 - 1200	Informatics: Melanoma Databases & Digital Patient Records	
	<i>Session Chairs: Graham Mann, Kerwin Shannon</i>		Parkside G07
	1100 - 1115	Development of informatics at MIA <i>Jonathan Stretch</i>	
	1115 - 1130	Database management in the UK <i>Katherine Acland</i>	
	1130 - 1145	Database management in the US <i>Jane Messina</i>	
	1145 - 1200	Panel Discussion	
	1200 - 1300	Rationalising melanoma management: comparative effectiveness research	
	<i>Session Chairs: Susan Neuhaus, David Ollila</i>		Parkside G07
	1200 - 1210	Economic considerations in melanoma care <i>Rachael Morton</i>	
	1210 - 1220	Economic issues facing melanoma services in the US <i>Jeffrey Gershenwald</i>	
	1220 - 1230	Health effectiveness modelling and the impact of imaging investigations <i>Taryn Bessen</i>	
1230 - 1240	The burden of follow-up: who should a melanoma unit see? <i>Mark Smithers</i>		

	1240 - 1250	Is melanoma follow up cost effective?	
		<u>Harald Hoekstra</u>	
	1250 - 1300	Discussion	
1300 - 1400	Multidisciplinary team meeting – Lunch with the Professors		
	Chairs: Rick Kefford, Vernon Sondak		
1400 - 1530	Pathology in multidisciplinary melanoma care in the molecular Era		
	<i>Session Chairs: Richard Scolyer, Martin Mihm</i>		Parkside 110 A & B Combined
1400 - 1530	1400 - 1415	The role of pathology review in multidisciplinary melanoma care	
		<u>Jane Messina</u>	
	1415 - 1430	Approaches to the diagnosis and management of Patients with histopathologically ambiguous primary melanocytic tumours	
		<u>Klaus Busam</u>	
	1430 - 1445	The role of FISH & CGH in the diagnosis of melanocytic tumours	
		<u>Pedram Gerami</u>	
	1445 - 1500	Tissue biomarkers for melanoma prognosis in 2010	
	<u>Bonnie Gould Rothberg</u>		
	1500 - 1515	Maximising the value of melanoma biospecimen bank	
		<u>Graham Mann</u>	
	1515 - 1530	Discussion	
1400 - 1530	Quality Assurance in Melanoma Surgery		
	<i>Session Chairs: Andrew Spillane, Dan Coit</i>		Parkside G07
1400 - 1530	1400 - 1410	QA In Melanoma Surgery: how do we provide the right care to the right patient at the right time?	
		<u>Vernon Sondak</u>	
	1410 - 1420	What we do to guarantee QA	
		<u>Jeffrey Gershenwald</u>	
	1420 - 1430	Quality assurance in the Netherlands	
	<u>Omgo Nieweg</u>		
	1430 - 1440	Quality Assurance in Melanoma Surgery - the evolving Melanoma Institute Australia (MIA) experience	
		<u>Andrew Spillane</u>	

	1440 - 1530	Discussion		
1530 - 1600		Afternoon Tea		
1600 - 1730		Advances in management of locoregional disease – Session Proudly Sponsored by Provectus		
	<i>Session Chairs: Mark Smithers, Carlo Riccardo Rossi</i>		Parkside 110 A & B Combined	
1600 - 1730	1600 - 1610	Electrochemotherapy with bleomycin: a local treatment with possible systemic implications <i>Alessandro Testori</i>		
	1610 - 1620	Percutaneous hepatic perfusion (Delcath procedure) for melanoma metastases to the liver <i>Jonathan Zager</i>		
	1620 - 1630	Phase I Evaluation of the intralesional administration of the oncolytic picornavirus, Coxsackievirus A21 (CAVATAKTM) in patients with late stage melanoma <i>Darren Shafren</i>		
	1630 - 1640	Chemoablation of metastatic melanoma with intralesional PV-10 <i>Sanjiv Agarwala</i>		
	1640 - 1650	Isolated limb infusion <i>Andrew Barbour</i>		
	1650 - 1700	OncoVEXGM-CSF: Phase 2 data and update on the ongoing pivotal Phase 3 trial <i>Robert Coffin</i>		
	1700 - 1710	Topical diphencyprone immunotherapy for extensive cutaneous metastatic melanoma <i>Diona Damian</i>		
	1710 - 1730	Discussion		
	1600 - 1730		Supportive Care	
		<i>Session Chairs: Fran Boyle, Phyllis Butow</i>		Parkside G07
1600 - 1730	1600 - 1615	Psychosocial care for melanoma patients: what do we know? <i>Phyllis Butow</i>		
	1615 - 1630	Supportive care needs of patients at high risk of melanoma: current research. <i>Nadine Kasparian</i>		
	1630 - 1645	Improving the measurement of Quality of Life in melanoma patients <i>Julie Winstanley</i>		
	1645 - 1700	Working with patients and families - fostering realistic optimism		

	<u>Stewart Dunn</u>
1700 - 1730	Discussion
1730 - 1830	Poster Session (IMSCC)
1830 - 1930	Keynote Address
<i>Session Chairs: Rick Kefford</i>	
	Parkside G07
1830 - 1930	Evolving melanoma therapeutics
	<u>Keith Flaherty</u>

Friday 5th November 2010

0715 - 0730	GSK Program: Adjuvant Therapy – What lies ahead
<i>Session Chairs: Richard Kefford & Peter Hersey</i>	
	Parkside 110A & 110B
0715 - 0730	What is the promise and risk of selective BRAF inhibitors in adjuvant therapy? <u>Lead discussants: Jeff Sosman, Reinhard Dummer</u>
0730 - 0745	How can we target immunotherapy more effectively? Biomarker studies <u>Lead discussants: Jonathan Cebon, Graham Mann, John Kirkwood</u>
0745 - 0800	What lies ahead in choice of antigens for immunotherapy? <u>Lead discussants: Rod Dunbar, Jurgen Becker</u>
0800 - 0815	Questions and Discussion
0830 - 1030	Targeted Therapies I
<i>Session Chairs: Dirk Schadendorf, Antoni Ribas</i>	
	Parkside Auditorium
0830 - 0900	Selective inhibition of oncogenic BRAF V600E/K/D by GSK2118436: Evidence of clinical activity in subjects with metastatic melanoma <u>Richard Kefford</u>
0900 - 0930	An open-label, multicenter phase 2 study of continuous oral dosing of RG7204 (PLX4032) in previously treated patients with BRAF V600E mutation-positive metastatic melanoma <u>Jeff Sosman</u>
0930 - 1000	Feedback inhibition of RAF/MEK signalling <u>Neal Rosen</u>
1000 - 1030	BRAF/CRAF switching <u>Richard Marais</u>

* Program is current as at 27th October and is subject to change.

1030 - 1100		Morning Tea
1100 - 1300	1100 - 1200	Adjuvant therapies – Session Proudly Sponsored by MSD
	<i>Session Chairs: Freidagund Meier, Dirk Schadendorf</i>	
	Parkside 110 A & B Combined	
	1100 - 1112	PEG intron, Ipilumimab <u>Alexander Eggermont</u>
	1112 - 1124	MAGE-3A vaccine studies. Current studies: interferon <u>John Kirkwood</u>
	1124 - 1136	Current Studies <u>Axel Hauschild</u>
	1136 - 1148	Adjunctive radiotherapy trial <u>Michael Henderson</u>
	1148 - 1200	Discussion
	1200 - 1300	Management of Cerebral Disease
	<i>Session Chairs: John Kirkwood, Mark Middleton</i>	
	Parkside 110 A & B Combined	
	1200 - 1210	Role of resection <u>Brinda Shivalingham</u>
	1210 - 1220	The role of the gamma knife on cerebral melanoma metastases <u>Michael Izard</u>
	1220 - 1230	Whole brain radiotherapy following local treatment of 1-3 intracranial metastases of melanoma - a phase III trial <u>Gerald Fogarty</u>
1230 - 1245	Cerebral disease in the age of targeted therapy <u>Keith Flaherty</u>	
1245 - 1300	Discussion	
1100 - 1210	Surgical management	
<i>Session Chairs: Jeffrey Gershenwald, Jonathan Stretch</i>		
Parkside G07		
1100 - 1107	Management of melanoma in Primary care in East of England <u>J. Garioch</u>	
1107 - 1114	Setting up an efficient and effective sentinel node biopsy service for malignant melanoma patients- the Norfolk and Norwich experience	

1100 - 1300		<u>M. Moncrieff</u>
	1114 - 1121	ODAM, A Novel Tight Junction Protein, Predicts Sentinel Node Metastasis in Cutaneous Melanoma
		<u>S. Gandhi</u>
	1121 - 1128	Preoperative Hybrid SPECT/CT detecting sentinel lymph nodes in cutaneous head and neck malignancies
		<u>J. Klode</u>
	1128 - 1135	Sentinel Node Positive Melanoma Patients- Is there a continued role for staging investigations prior to a completion lymphadenectomy?
		<u>J. Spillane</u>
	1135 - 1142	Disease-Specific Mortality in Sentinel Node-Negative Melanoma Patients
		<u>E. Whitman</u>
	1142 - 1149	Lymph node ratio should be recognised as a stratification factor in melanoma surgical trials
		<u>A. Spillane</u>
	1149 - 1156	Lymph node management of patients diagnosed with invasive melanoma in New South Wales
		<u>C. Madronio</u>
	1156 - 1203	Chronic Pain after Surgery for Malignant Melanoma
		<u>H. Hømyr</u>
1203 - 1210	Discussion	
1210 - 1300	Non Surgical Management	
<i>Session Chairs: Rick Essner, Catriona McNiell</i>		Parkside G07
1210 - 1217	Merkel cell Carcinoma : The Westmead hospital experience and management approach.	
	<u>J. Howle</u>	
1217 - 1234	Adoptive Transfer of Short-Term Cultured Tumor Infiltrating Lymphocytes in Metastatic Melanoma Patients: Clinical Results	
	<u>J. Schachter</u>	
1234 - 1241	L19IL2 monoclonal antibody-cytokine fusion protein in combination with DTIC in chemo-naïve stage IV melanoma patients.	
	<u>B. Weide</u>	
1241 - 1248	Expression of MAGE-A3 among stage IIIB-C melanoma patients: preliminary results of screening tests for the DERMA trial	

		<i>J. Grob</i>	
	1248 - 1300	Discussion	
1300 - 1400	BMS Lunch Symposium		
<i>Session Chairs: Peter Hersey</i>			Parkside 110 A & B Combined
	1300 - 1305	Introduction <i>Peter Hersey</i>	
	1305 - 1320	Cancer Vaccines. Successes and failures <i>Jonathan Cebon</i>	
	1320 - 1340	Overcoming Immunologic Tolerance to Melanoma: Targeting CTLA-4 <i>F. Stephen Hodi</i>	
		Discussion	
1400 - 1530	Merkel cell carcinoma		
<i>Session Chairs: Gerald Fogarty, Vernon Sondak</i>			Parkside 110 A & B Combined
1400 - 1530	1400 - 1420	What's new in Merkel cell carcinoma? <i>Jürgen Becker</i>	
	1420 - 1450	MCC Therapeutics Debate: What is the mainstay of MCC treatment in 2010? <i>Daniel Coit and Michael Poulsen</i>	
	1450 - 1500	Update: systemic therapies for MCC <i>Alex Guminski</i>	
	1500 - 1510	Towards prospective trials in MCC - the importance of multidisciplinary collaboration <i>George Hruby</i>	
	1510 - 1530	Panel Discussion	
1400 - 1530	Communication Workshop		
<i>Session Chairs: Fran Boyle</i>			Parkside G07
	1400 - 1530	Looking into the sun - staying healthy in melanoma care <i>Stewart Dunn</i>	
1530 - 1600	Afternoon Tea		
	1600 - 1630	What makes a melanoma centre?	
<i>Session Chairs: Josep Malvehy, Harald Hoekstra</i>			Parkside 110 A & B Combined
	1600 - 1610	What makes a melanoma centre?	

* Program is current as at 27th October and is subject to change.

1600 - 1730		<u>Vernon Sondak</u>	
	1610 - 1620	Melanoma in China	
		<u>Jun Guo</u>	
	1620 - 1630	Melanoma in Japan	
		<u>Hisashi Uhara</u>	
	1630 - 1700	Focus Group Reports	
			Parkside 110 A & B Combined
	1630 - 1635	Quality Assurance	
		<u>Andrew Spillane</u>	
	1635 - 1640	Informatics	
		<u>Jonathan Stretch</u>	
	1640 - 1645	Economics	
		<u>Susan Neuhaus</u>	
	1645 - 1650	Supportive Care	
		<u>Fran Boyle</u>	
	1650 - 1655	Web-based information for patients and carers	
		<u>Valerie Guild</u>	
	1655 - 1705	Discussion	
	1705 - 1740	Towards International Guides for Melanoma	
		<i>Session Chairs: Graham Stevens, Alistair Cochran</i>	Parkside 110 A & B Combined
1705 - 1712	NCNN guidelines		
	<u>Daniel Coit</u>		
1712 - 1719	European Guidelines		
	<u>Claus Garbe</u>		
1719 - 1726	How do we develop international guidelines? The Australian/New Zealand model		
	<u>John Thompson</u>		
1726 - 1735	Panel Discussion		
1735-1740	Cnetres meeting: closing remarks John Thompson		
1600 - 1700	Prevention and early detection		

<i>Session Chairs: Peter Soyer, Diona Damian</i>		Parkside G07
1600 - 1730	1600 - 1607	Personal, time-stamped dosimeter readings reveal that high UVR exposure doses are correlated to sun risk behaviour in non-outdoor workers <i><u>E. Thieden</u></i>
	1607 - 1614	Serum vitamin D levels in melanoma patients on follow up in Scotland <i><u>R. Mackie</u></i>
	1614 - 1621	Interdependence between body surface area and UVB dose in vitamin D production: A randomized controlled trial. <i><u>M. Boqh</u></i>
	1621 - 1628	Oxidative stress in human skin cells and its association with mitochondrial damage and skin cancer <i><u>M. Birch-Machin</u></i>
	1628 - 1635	Risk of non-melanoma cancer in CDKN2A carriers <i><u>B. Mukherjee</u></i>
	1635 - 1642	Early detection of melanoma based on Digital Follow-Up of high-risk patients. Ten years Spanish experience of a prospective surveillance. <i><u>C. Carrera</u></i>
	1642 - 1649	Seasonal variability in the diagnosis of primary cutaneous melanoma – a comparison of the Northern & Southern hemispheres <i><u>J. Kim</u></i>
	1649 - 1700	Discussion

<i>Session Chairs: Markus Frank (USA) & Jonathan Cebon (Australia)</i>		Parkside Auditorium
1100 - 1124	Slow cycling self renewing JARID1B-positive cells are essential for long-term maintenance of malignant melanoma <i>Meenhard Herlyn</i>	
1124 - 1148	Melanoma progression <i>Mark Shackleton</i>	
1148 - 1212	Stem Cells <i>Marcus Bosenberg</i>	
1212 - 1236	Mechanisms of melanoma stem cell-driven tumor growth <i>Tobias Schatton</i>	
1236 - 1300	Human Melanoma Initiating Cells Express the Neural Crest Nerve Growth Factor p75 Receptor CD271 <i>Alexander Boiko</i>	
1300 - 1400	BMS Lunch Symposium	
<i>Session Chairs: Peter Hersey (Australia)</i>		Parkside 110A & B Combined
1300 - 1305	Introduction <i>Peter Hersey</i>	
1305 - 1320	Cancer Vaccines. Successes and failures <i>Jonathan Cebon</i>	
1320 - 1340	Overcoming Immunologic Tolerance to Melanoma: Targeting CTLA-4 <i>F. Stephen Hodi</i>	
	Discussion	
1400 - 1530	Animal Models	
<i>Session Chairs: Lionel Larue (France) & Graeme Walker (Australia)</i>		Parkside Auditorium
1400 - 1418	Interferon- links UV to melanocyte activation and promotes melanomagenesis <i>Glenn Merlino</i>	
1418 - 1436	Determinants of melanoma progression identified from a series of transgenic zebrafish <i>Adam Hurlstone</i>	
1436 - 1454	BRAF zebrafish <i>Liz Patton</i>	

1454 - 1512	A murine model for de novo melanoma	
	<u>Masashi Kato</u>	
1512 - 1530	p53 prevents progression of nevi to melanoma predominantly through cell cycle regulation	
	<u>Neil Box</u>	
1530 - 1600	Afternoon Tea	
1600 - 1730	Cell Growth Regulation	
<i>Session Chairs: Dot Bennett (UK) & Wolfgang Weninger (Australia)</i>		Parkside Auditorium
1600 - 1618	A Wnt-ery response to genotoxic injury: Effects of Wnt5A on cell cycle, p21 and DNA repair.	
	<u>Ashani Weeraratna</u>	
1618 - 1636	BRAF-regulated targets in cell proliferation and apoptosis: Implications for therapeutic resistance	
	<u>Andrew Aplin</u>	
1636 - 1654	UVR-induced DNA damage checkpoint	
	<u>Brian Gabrielli</u>	
1654 - 1712	Real-time Imaging of Cell Cycle Progression in Melanoma	
	<u>Nikolas Haass</u>	
1712 - 1730	<u>TBC</u>	
	<u>TBC</u>	
1730 - 1830	Poster Session A	

Saturday 6th November

0830 - 1030	Targeted Therapies II	
<i>Session Chairs: Christoph Hoeller (Austria) & Paul Chapman (USA)</i>		Parkside Auditorium
0830 - 0900	PARP and MEK inhibitors	
	<u>Mark Middleton</u>	
0900 - 0930	Understanding intrinsic and acquired resistance to BRAF inhibitors in melanoma	
	<u>Keiran Smalley</u>	
0930 - 1000	AZD6244 and development of resistance	
	<u>Reinhard Dummer</u>	
1000 - 1030	Induction of apoptosis in melanoma cells by inhibitors of mutated BRAF. The key to therapeutic success?	
	<u>Peter Hersey</u>	

* Program current as of 27 October 2010 and is subject to change.

1100 - 1300	Targeted Therapies III	
<i>Session Chairs: Michael Brown (Australia)</i>		Parkside Auditorium
1100 - 1124	Adoptive cell transfer immunotherapy with TCR transgenic lymphocytes	
	<u>Antoni Ribas</u>	
1124 - 1148	Tumor immunology meets tumor biology: Understanding how progressively growing autochthonous melanomas evade vaccine-induced T cell responses in genetically engineered mice	
	<u>Thomas Tueting</u>	
1148 - 1212	TBC	
	<u>Grant McArthur</u>	
1212 - 1236	Adaptation to ER Stress as a Mechanism of Resistance of Melanoma to Treatment	
	<u>X. D. Zhang</u>	
1236 - 1300	Transcriptional modules predict MEK addiction and response to selumetinib (AZD6244)	
	<u>Jonathan. Dry</u>	
1300 - 1400	Lunch	
1300 - 1400	Advanced Melanoma – Finding a Tailored Solution for Patients (Roche Symposium)	
<i>Session Chairs: Richard Kefford (Australia)</i>		Parkside 110A
1300 - 1305	Opening Remarks	
	<u>Richard Kefford</u>	
1305 - 1315	The Evolution of Treatment for Advanced Melanoma: From Chemotherapy to Individualized Targeted Therapies	
	<u>Axel Hauschild</u>	
1315 - 1325	Pivotal Signal Transduction Pathways in Melanoma	
	<u>Grant McArthur</u>	
1325 - 1340	Advances in RAF Pathway Inhibitors for Advanced Melanoma	
	<u>Jeffrey Sosman</u>	
1340 - 1350	Q&A and Closing Remarks	
1400 - 1530	Cell & Tumour Biology I	
<i>Session Chairs: Helmut Schaidler (Austria) & Kiarash Khosrotehrani (Australia)</i>		Parkside 110A
1400 - 1413	p16INK4A regulates G0-G1 entry and promotes apoptosis via CDK3/CCNC	
	<u>D. Hogg</u>	

1400 - 1530	1413 - 1426	Bone morphogenetic protein and nodal regulate adhesion and migration in melanoma cells and confer a malignant phenotype to melanocytes <u>C. Busch</u>
	1426 - 1439	Metastatic melanoma and breast cancer cells with imposed glycolytic metabolism fail to metastasize <u>M. Berridge</u>
	1439 - 1452	GLI2, a new marker of melanoma progression? <u>A. Mauviel</u>
	1452 - 1505	Loss of E-cadherin increases metastatic potential of melanoma <u>L. Larue</u>
	1505 - 1518	Long-Term Exposure to the B-RAFV600E Inhibitor PLX4720 Results in Melanoma Cells with Increased Activation of ERK1/2 and High Proliferation Potential <u>F. Lai</u>
	1518 - 1531	NR4A nuclear receptors link MC1R signalling to melanocytic cytoprotection. <u>A. Smith</u>
	1400 - 1530	Preclinical Studies I
	<i>Session Chairs: Jeffrey Lee (USA) & Barbara Bedogni (USA)</i>	
		Parkside 110B
1400 - 1530	1400 - 1413	Cell Senescence in Cell-Based Screening for Melanoma/Cancer Drug Discovery <u>D. Bennett</u>
	1413 - 1426	Targeting XIAP to increase endoplasmic reticulum stress-induced apoptosis for melanoma therapy <u>D. Hill</u>
	1426 - 1439	Metastatic melanoma cells are sensitive to drugs inducing endoplasmic reticulum stress-mediated apoptosis <u>D. Beck</u>
	1439 - 1452	Inhibition of the EGF-receptor as a pharmacological strategy in treatment regimen for metastatic melanoma - data from preclinical models <u>C. Hoeller</u>
	1452 - 1505	Modulation of NOXA and MCL-1 as a Tactic for Sensitizing Melanoma Cells to the BH3-mimetic ABT-737 <u>N. Mohana Kumaran</u>
	1505 - 1518	Tropomyosin Tm5NM1: A Novel Target for Melanoma Chemotherapy <u>J. Stehn</u>
	1518 - 1531	Generation of IL7-dependent melanoma-specific human T cell clones

		<i>R. Dunbar</i>	
1400 - 1530		Microenvironment & Genomics	
1400 - 1530	Session Chairs: <i>Boris Bastian (USA) & Therese Becker (Australia)</i>		Parkside Auditorium
	1400 - 1413	Angiotropism and extravascular migratory metastasis: Update with gene expression profiling of human primary angiotropic melanoma	
		<i>R. Barnhill</i>	
	1413 - 1426	The vascular bed, vessel stabilization and maturation affect the resistance to anti-angiogenic therapy in malignant melanoma	
		<i>I. Helfrich</i>	
	1426 - 1439	BRAF mutation, NRAS mutation and absence of an immune-related expressed gene profile predict poor outcome in surgically resected stage III melanoma	
		<i>G. Mann</i>	
	1439 - 1452	Somatic Alterations in the Melanoma Genome: A High-Resolution Array Based Comparative Genomic Hybridization Study	
		<i>R. Kumar</i>	
	1452 - 1505	Clonal tumor profiling of malignant melanoma genomes	
	<i>A. Sekulic</i>		
1505 - 1518	Genetic alterations in NRAS related pathways: identification of three distinct molecular signatures in Acral Lentiginous Melanoma		
	<i>S. Puig</i>		
1518 - 1531	Analysis of KIT, BRAF, NRAS and PDGFRA Aberrations in 565 Chinese Melanoma Patients		
	<i>Y. Kong</i>		
1530 - 1600		Afternoon tea	
1600 - 1730		Cell & Tumour Biology II	
	Session Chairs: <i>Véronique Winnepenninckx (Netherlands) & Helen Rizos (Australia)</i>		Parkside 110A
	1600 - 1613	Regulation of Melanoma Phenotype Switching.	
		<i>K. Hoek</i>	
	1613 - 1626	miR-193b regulates multiple key pathways in melanoma: A new link to Mcl-1	
		<i>V. Tron</i>	
1626 - 1639	The pigment cell specific microRNA, miR-211, as a novel tumour suppressor for melanoma.		

1600 - 1730		<u>S. Woods</u>	
	1639 - 1652	Humans exposed to intermittent doses of simulated solar UVR show differential expression of microRNAs in their melanocytes	
		<u>M. Harter</u>	
	1652 - 1705	The role of RNA editing enzyme ADAR1 in melanoma	
		<u>MJ. Besser</u>	
	1705 - 1718	Oncogenic BRAFV600E induces expression of neuronal differentiation marker MAP2 in melanoma cells by promoter demethylation and down-regulation of transcription repressor HES1	
		<u>V. Setaluri</u>	
	1718 - 1731	To age or to die - oncogene-induced senescence in melanocytes	
		<u>C. Leikam</u>	
1600 - 1730		Animal Models & Preclinical Studies II	
		<i>Session Chairs: Ed de Fabo (USA) & Marcus Bosenberg (USA)</i>	Parkside 110B
1600 - 1730	1600 - 1613	Neonatal UV irradiation promotes the outgrowth of UV initiated melanomas: a role or mast cell-dependent neonatal immune tolerance.	
		<u>F. Noonan</u>	
	1613 - 1626	Autochthonous primary and metastatic melanomas in Hgf-Cdk4R24C mice evade T cell-mediated immune surveillance	
		<u>J. Landsberg</u>	
	1626 - 1639	Differential roles of the pRb and p53 pathways in naevo and melanoma genesis	
		<u>G. Walker</u>	
	1639 - 1652	Development of a somatic cell gene transfer mouse model of melanoma	
		<u>S. Holmen</u>	
	1652 - 1705	Local cure of melanoma in mice and dogs by intratumoral injection of EBC46.	
		<u>G. Boyle</u>	
1705 - 1718	Targeting Circulating Tumor Cells with Nanoliposomes Containing siRNA Directed Against IL-8 Disrupts Interaction with Neutrophils and Thereby Decreases Lung Metastasis Development		
		<u>G. Robertson</u>	
	1718 - 1731	T-cell and clinical responses after therapy with murine monoclonal antibody to anti-OX40: Results from a	

		phase I clinical trial	
		<u>W. Urba</u>	
1600 - 1730	Epidemiology & Preclinical Studies III		
	<i>Session Chairs: Nancy Thomas (USA) & Sancy Leachman (USA)</i>		Parkside Auditorium
	1600 - 1613	Interaction of sun exposure and CDKN2A in the development of cutaneous melanoma	
		<u>M. Berwick</u>	
	1613 - 1626	Sunbed Use during Adolescence and Early Adulthood is Associated with Increased Risk of Early-onset Melanoma	
		<u>A. Cust</u>	
	1626 - 1639	Melanoma cases with multiple independent primary melanomas show the strongest evidence for a heritable predisposition	
		<u>L. Cannon-Albright</u>	
	1639 - 1652	Disentangling the genetic mechanisms underlying melanoma occurrence by pathway-based analysis of genome-wide data	
		<u>F. Demenais</u>	
1600 - 1730	1652 - 1705	Cutaneous Manifestations of the Selective BRAF Inhibitor GSK2118436.	
		<u>J. Livingston</u>	
	1705 - 1718	Chemokine mediated enhancement of melanoma immunotargeting in situ and DNA vaccination.	
		<u>V. Alexeev</u>	
	1718 - 1731	Identification of circulating malignant melanoma-initiating cells	
		<u>J. MA</u>	
1730 - 1830	Poster Session (SMR)		
1730 - 1830	Abbott Program: Recent Advances in the Diagnosis of Melanoma		
	<i>Session Chairs: Richard Scolyer</i>		Parkside 110A
	1730 - 1800	Targeting Immunotherapy in Patients with Melanoma	
		<u>Peter Hersey</u>	
	1800 - 1830	FISH for Melanoma diagnosis – the MSKCC experience	
		<u>Klaus Busam</u>	

Sunday 7th November

0830 - 1030	Melanoma Tumour Biology	
<i>Session Chairs: Kowichi Jimbow (Japan) & Nikolas Haass (Australia)</i>		Parkside Auditorium
0830 - 0854	TBC <i>David Fisher</i>	
0854 - 0918	Autophagy <i>Maria S. Soengas</i>	
0918 - 0942	A role for ATF2 in regulating MITF and melanoma development <i>Ze'ev Ronai</i>	
0942 - 1006	Oncogene-induced melanocyte senescence <i>Helen. Rizos</i>	
1006 - 1030	Signalling and monitoring phenotype switching in melanoma cell subpopulations <i>Colin Goding</i>	
1030 - 1100	Morning Tea	
1100 - 1300	Melanoma Gene Discovery	
<i>Session Chairs: Ichiro Okamoto (Austria) & Pam Pollock (Australia)</i>		Parkside Auditorium
1100 - 1120	Towards Deciphering the Genetic Landscape of Melanoma <i>Yardena Samuels</i>	
1120 - 1140	Next Generation Sequencing for Single Nucleotide Variant (SNV) Discovery in Melanoma <i>Ruth Halaban</i>	
1140 - 1200	Complete exome resequencing reveals inactivating mutations in a novel metastasis suppressor on chromosome 3 in uveal melanoma <i>William Harbour</i>	
1200 - 1220	GenoMEL GWAS <i>Tim Bishop</i>	
1220 - 1240	An Australian Genome-Wide Association Study to Identify Melanoma Predisposition Genes <i>Nick Hayward</i>	
1240 - 1300	Melanoma predisposition gene discovery using a genome-wide sequencing approach <i>Kevin Brown</i>	
1300 - 1400	SMR Congress Awards and Close	

* Program current as of 27 October 2010 and is subject to change.